Tobias Struller, Manager, Process Performance & Qualification

Dedicated facilities with dedicated filling lines are increasingly being replaced by multiproduct facilities as more and more specialized therapeutics, developed for targeted patient populations within a specific therapy area, are reaching the market. In this article, Tobias Struller, Manager, Process Performance & Qualification at Simtra BioPharma Solutions’ Halle/Westfalen, Germany, facility, provides insight into the challenges of manufacturing cytotoxic and noncytotoxic drugs together in a multiproduct facility.